cystic
fibrosi
cf
inherit
disord
due
rang
mutat
cf
gene
affect
campregul
chlorid
channel
cf
transmembran
regul
cftr
lung
lead
dehydr
periciliari
layer
mucociliari
escal
perform
function
clear
particl
includ
microorgan
airway
patient
develop
acut
later
chronic
respiratori
infect
lead
cycl
damag
less
abil
clear
infect
rang
microorgan
caus
infect
differ
patient
without
cf
commonest
pathogen
staphylococcu
aureu
pseudomona
aeruginosa
antibiot
use
clear
earli
infect
treat
acut
exacerb
chronic
infect
reduc
frequenc
exacerb
use
longterm
system
inhal
drug
treatment
major
impact
qualiti
surviv
patient
cf
still
howev
question
best
way
diagnos
infect
use
antibiot
patient
need
repeat
cours
lifetim
bacteria
chronic
infect
differ
characterist
caus
acut
infect
includ
atyp
phenotyp
lead
difficulti
identifi
speci
laboratori
antibiot
resistanceboth
infect
innat
resist
bacteria
also
develop
multiresist
strainsi
increas
challeng
cf
although
infect
remain
main
caus
morbid
mortal
recent
advanc
understand
role
differ
speci
mode
pathogen
hold
much
promis
improv
treatment
review
focu
recent
advanc
cf
microbiolog
look
relev
diagnosi
manag
infect
highlight
area
need
develop
specif
antibiot
treatment
strategi
practic
guidelin
diagnosi
infect
discuss
well
review
elsewher
staphylococcu
aureu
staphylococcu
aureu
frequent
pathogen
young
infant
cf
uncommon
caus
lower
respiratori
tract
infect
patient
without
cf
found
bronchoalveolar
lavag
bal
fluid
cf
children
averag
age
month
often
persist
despit
treatment
use
antistaphylococc
antibiot
clinic
effect
role
longterm
prophylaxi
aureu
uncertain
smallcoloni
variant
scv
phenotyp
aureu
common
cf
patient
bacteria
adapt
includ
antibiot
resist
abil
surviv
insid
host
cell
may
contribut
persist
cf
airway
coloni
small
nonpig
slow
grow
may
miss
routin
cultur
use
certain
media
may
make
easier
recogn
slow
growth
make
identif
suscept
test
autom
system
unreli
longitudin
studi
shown
significantli
higher
rate
genom
alter
persist
clone
aureu
cf
sputum
nose
healthi
individu
presum
respons
select
pressur
host
respons
repeat
use
antibiot
cf
potenti
mechan
genom
alter
bacteriophag
mobil
hypermut
hypermut
bacteria
mutat
dna
repair
error
avoid
gene
spontan
mutat
rate
rais
mutat
strain
aureu
identifi
cf
due
inactiv
dna
mismatch
repair
gene
mut
anoth
mechan
may
help
longterm
surviv
aureu
cf
lung
abil
form
biofilm
may
import
infect
medic
devic
prosthes
artifici
heart
valv
orthopaed
implant
role
biofilm
cf
howev
unclear
need
investig
increas
methicillinresist
aureu
mrsa
gener
popul
caus
concern
mani
countri
organ
necessarili
pathogen
rather
treatment
option
limit
mechan
resist
methicillin
confer
resist
blactam
penicillin
cephalosporin
mani
strain
mrsa
also
acquir
resist
unrel
antibiot
quinolon
aminoglycosid
major
attempt
made
control
spread
resist
aureu
success
uk
howev
preval
mrsa
cf
patient
increas
vancomycinresist
aureu
although
rare
seen
noncf
patient
treatment
altern
glycopeptid
avail
experi
cf
limit
sever
clearanc
regimen
propos
surprisingli
success
nonencapsul
nontyp
b
capsul
haemophilu
influenza
common
infant
young
children
cf
older
patient
littl
inform
epidemiolog
longterm
infect
h
influenza
cf
recent
studi
show
infect
cystic
fibrosi
infect
dynam
process
patient
sequenti
infect
differ
strain
repeat
isol
clone
seen
cf
patient
increas
antibiot
resist
time
patient
infect
h
influenza
resist
two
antibiot
class
resist
includ
decreas
suscept
ciprofloxacin
rare
seen
outsid
cf
onethird
patient
hypermut
strain
anoth
cf
studi
hypermut
h
influenza
associ
mutat
mut
month
organ
gradual
becam
resist
antibiot
use
treat
patient
persist
h
influenza
may
link
abil
form
biofilm
shown
otiti
media
noncf
patient
structur
consist
biofilm
observ
bal
asymptomat
cf
patient
clinic
concentr
azithromycin
shown
inhibit
biofilm
format
reduc
establish
biofilm
h
influenza
vitro
without
affect
bacteri
growth
although
streptococcu
pneumonia
common
respiratori
tract
pathogen
unusu
cf
rate
colon
rang
differ
seri
recent
studi
show
multiresist
possibl
hypermut
isol
cf
streptococcu
pneumonia
cf
respiratori
sampl
better
produc
biofilm
vitro
blood
cultur
isol
noncf
patient
suggest
organ
abil
persist
cf
lung
still
howev
unclear
whether
pneumonia
act
harmless
commens
cf
role
acut
exacerb
facilit
infect
pathogen
pseudomona
aeruginosa
common
pathogen
cultur
cf
sputum
may
seen
earli
infanc
often
cultur
intermitt
childhood
eventu
chronic
infect
develop
lead
faster
declin
lung
function
age
infect
becom
chronic
increas
better
treatment
cf
particularli
due
practic
intens
treatment
antipseudomon
antibiot
p
aeruginosa
first
cultur
delay
onset
chronic
infect
increas
life
expect
cf
patient
may
clinic
stabl
chronic
infect
p
aeruginosa
repeat
episod
acut
exacerb
increas
breathless
sputum
product
feel
unwel
exacerb
also
mark
reduct
lung
function
exacerb
gener
treat
combin
system
antibiot
inhal
antibiot
commonli
colistin
tobramycin
use
help
clear
earli
infect
effect
longterm
prophylaxi
reduc
frequenc
acut
exacerb
infect
chronic
recent
longterm
azithromycin
prophylaxi
use
cf
follow
experi
treat
diffus
panbronchiol
condit
describ
japan
also
lead
chronic
infect
p
aeruginosa
benefit
longterm
oral
azithromycin
shown
cf
fewer
exacerb
better
lung
function
reduct
inflammatori
marker
macrolid
antibiot
may
act
antiinflammatori
activ
modifi
pathogen
p
aeruginosa
see
earli
epidemiolog
studi
show
crossinfect
p
aeruginosa
rare
cf
patient
infect
uniqu
strain
presum
acquir
environ
sibl
strain
unclear
due
crossinfect
acquisit
common
sourc
contrast
recent
studi
reveal
spread
socal
epidem
strain
multiresist
would
necessarili
particular
concern
except
exampl
liverpool
epidem
strain
le
may
pathogen
superinfect
patient
alreadi
colon
strain
p
aeruginosa
infect
patient
exacerb
time
hospit
cours
antibiot
furthermor
patient
first
infect
multiresist
epidem
p
aeruginosa
earli
aggress
treatment
often
fail
led
polici
uk
segreg
patient
epidem
strain
le
genom
recent
sequenc
work
progress
determin
basi
transmiss
enhanc
pathogen
strain
le
hyperproduc
pyocyanin
put
pathogen
factor
effect
includ
reduc
beat
respiratori
epithelium
cilia
induct
neutrophil
apoptosi
regul
quorum
sens
qs
lasa
qs
system
extens
studi
p
aeruginosa
molecular
signal
allow
commun
bacteria
secret
certain
concentr
trigger
express
gene
p
aeruginosa
includ
code
pathogen
factor
biofilm
format
motil
thought
gene
p
aeruginosa
regul
qs
mechan
allow
precis
regul
gene
respons
environment
stimuli
cell
densiti
plant
natur
form
antagonist
qs
molecul
acyl
homoserin
lacton
defenc
mechan
qs
therefor
potenti
target
new
antimicrobi
therapi
laboratori
bacteria
isol
chronic
infect
patient
differ
usual
p
aeruginosa
cultur
acut
infect
clonal
bacteria
form
coloni
differ
appear
refer
coloni
morphotyp
classic
cf
isol
mucoid
due
hyperproduct
algin
morphotyp
includ
bacteria
look
like
coliform
nonpig
form
slowgrow
scv
latter
hydrophob
reduc
swim
motil
form
good
biofilm
vitro
may
miss
routin
laboratori
take
h
appear
phenotyp
variat
restrict
coloni
morpholog
includ
type
iii
secret
auxotrophi
lipopolysaccharid
lp
modif
smooth
rough
resist
hypersuscept
antibiot
variabl
antibiot
suscept
popul
bacteria
cf
sputum
includ
differ
bacteria
clone
morphotyp
result
suscept
test
poorli
reproduc
result
may
depend
bacteria
pick
test
role
antimicrobi
suscept
test
help
clinician
chose
antibiot
treat
acut
exacerb
cf
controversi
anecdot
report
poor
correl
antimicrobi
suscept
treatment
acut
exacerb
method
improv
detect
resist
subpopul
describ
howev
big
studi
correl
antibiot
resist
clinic
respons
show
lung
function
forc
expiratori
volum
one
second
improv
patient
spite
treatment
antibiot
p
aeruginosa
resist
vitro
antibiot
seldom
ever
erad
chronic
infect
p
aeruginosa
cf
lung
even
resolut
symptom
sign
exacerb
may
match
signific
reduct
bacteri
load
may
therefor
antibiot
effect
without
actual
inhibit
kill
bacteriath
socal
subminimum
inhibitori
concentr
mic
effect
may
also
explain
success
treatment
infect
antibiot
even
though
bacteria
resist
exampl
submic
concentr
ceftazidim
inhibit
attach
cell
ciprofloxacin
reduc
algin
product
although
p
aeruginosa
intrins
resist
azithromycin
may
reduc
pathogen
inhibit
qs
biofilm
format
pseudomona
aeruginosa
innat
resist
mani
antibiot
acquir
resist
increas
synergi
test
advoc
way
find
combin
antibiot
effect
multiresist
p
aeruginosa
timekil
curv
chequerboard
method
multipl
combin
bactericid
test
mcbt
commonli
use
method
synergi
shown
vitro
differ
result
howev
obtain
differ
method
accept
refer
standard
studi
attempt
correl
result
synergi
test
clinic
outcom
one
random
prospect
studi
compar
mcbt
tradit
singl
antibiot
suscept
test
determin
treatment
acut
exacerb
rang
multiresist
speci
cf
includ
p
aeruginosa
stenotrophomona
maltophilia
achromobact
xylosoxidan
burkholderia
cepacia
complex
bcc
show
better
outcom
antibiot
chosen
basi
result
mcbt
role
current
method
synergi
test
controversi
definit
need
clinic
valid
vitro
test
guid
treatment
multiand
panresist
bacteria
acut
exacerb
patient
receiv
lung
transplant
rapid
develop
antibioticresist
p
aeruginosa
may
partli
due
presenc
hypermut
strain
bacteria
defect
abil
correct
mistak
dna
replic
rang
mutat
includ
mismatch
repair
gene
mut
strong
mutat
may
mutat
rate
high
compar
normal
rate
one
studi
show
hypermut
cf
patient
chronic
infect
p
aeruginosa
highest
preval
describ
natur
system
sinc
hypermut
shown
chronic
lung
diseas
hypermut
strain
found
amongst
isol
p
aeruginosa
earli
infect
suggest
may
advantag
initi
infect
well
chronic
infect
howev
infrequ
question
whether
mutat
strain
would
disadvantag
high
rate
damag
spontan
mutat
howev
abil
rapidli
adapt
chang
environ
becom
advantag
ecolog
nich
repeatedli
expos
antibiot
larg
popul
bacteria
cf
lung
organ
mutat
antibiot
resist
may
present
even
antibiot
given
practic
cf
give
two
antipseudomon
antibiot
reduc
emerg
resist
strain
recent
observ
hypermut
cf
show
potenti
import
recommend
common
bacteria
seen
cf
p
aeruginosa
form
biofilm
vitro
observ
biofilmlik
aggreg
expector
sputum
biofilm
commun
bacteria
within
acellular
matrix
usual
attach
surfacein
cf
respiratori
epithelium
patient
biofilm
may
also
contain
speci
bacteria
hostderiv
product
bacteria
biofilm
difficult
erad
resist
host
immun
system
antibiot
resist
varieti
mechan
antibiot
may
bind
extracellular
matrix
reduc
activ
area
poor
oxygen
low
ph
also
bacteria
biofilm
live
gradient
oxygen
nutrient
metabolit
therefor
divers
adapt
differ
microenviron
growth
phase
activ
divid
dormant
may
affect
suscept
antibiot
variabl
antibiot
suscept
seen
popul
bacteria
cultur
singl
sputum
vitro
condit
may
bacteria
present
biofilm
fragment
sputum
organ
may
adapt
rang
differ
activ
concentr
antibiot
encount
differ
level
biofilm
concern
laboratori
method
develop
measur
antibiot
suscept
plankton
bacteria
caus
acut
infect
may
relev
cf
led
develop
method
test
antibiot
suscept
biofilm
evalu
one
method
determin
optimum
antibiot
clear
chronic
infect
progress
recent
studi
use
whole
genom
analysi
show
accumul
mutat
gene
p
aeruginosa
year
patient
cf
evolutionari
diverg
thought
favour
adapt
earli
late
isol
p
aeruginosa
patient
compar
look
gene
one
commonest
mutat
la
r
principl
qs
regul
p
aeruginosa
interfer
mani
pathogen
factor
includ
biofilm
format
difficult
reconcil
propos
import
biofilm
persist
infect
gene
commonli
mutat
chronic
colon
also
involv
pathogen
eg
exo
regul
type
iii
secret
antibiot
resist
gene
code
compon
multidrug
efflux
pump
pictur
may
emerg
therefor
organ
great
abil
adapt
environ
becom
less
pathogen
time
presum
devic
longterm
surviv
host
recent
studi
shown
antibioticresist
gene
overrepres
hypermut
hypermut
may
play
import
gener
role
genom
evolut
adapt
cf
lung
pseudomona
aeruginosa
burkholderia
spp
see
cf
rang
strategi
enabl
persist
cf
lung
includ
constantli
adapt
chang
environ
bacteria
difficult
erad
also
phenotyp
divers
observ
laboratori
make
design
valid
new
test
antibiot
suscept
difficult
futur
research
need
understand
mechan
pathogen
persist
treatment
prevent
clear
infect
develop
appropri
laboratori
test
suscept
relev
clinic
outcom
isol
speci
b
cepacia
previous
pseudomona
cepacia
shown
consist
phenotyp
similar
genotyp
distinct
genomovar
subsequ
number
genomovar
increas
achiev
speci
statu
present
socal
bcc
compris
least
speci
natur
soil
bacteria
found
rhizospher
plant
symbiont
pathogen
opportunist
pathogen
affect
patient
sever
immunosuppress
follow
contamin
fluid
medic
devic
caus
signific
primari
infect
patient
cf
chronic
granulomat
diseas
cgd
patient
cgd
specif
immun
defect
oxid
burst
pathway
reason
associ
cf
still
unknown
patient
noncf
bronchiectasi
get
infect
bcc
complex
organ
rang
pathogen
factor
mani
regul
qs
system
similar
p
aeruginosa
burkholderia
spp
resist
colistin
often
multior
even
panresist
combin
antibiot
effect
vitro
littl
evid
correl
result
clinic
respons
treatment
import
bcc
cf
first
recogn
follow
outbreak
strain
burkholderia
cenocepacia
common
uk
canada
highli
transmiss
pathogen
led
mani
death
due
rapidli
progress
pneumonia
sometim
bacteraemia
refer
cepacia
syndrom
bcc
surviv
well
natur
healthcar
environ
strain
notabl
lineag
b
cenocepacia
easili
spread
patient
control
reduc
crossinfect
includ
segreg
patient
main
reason
infect
mortal
declin
significantli
uk
common
speci
seen
burkholderia
multivoran
new
infect
caus
unrel
clone
suggest
environment
sourc
rather
persontoperson
spread
infect
bcc
common
older
cf
patient
occur
time
patient
life
cepacia
syndrom
occur
organ
first
acquir
unexpectedli
mani
year
initi
infect
frequent
due
b
cenocepacia
howev
b
multivoran
burkholderia
dolosa
also
caus
cepacia
syndrom
potenti
pathogen
factor
lp
specif
cytotoxin
abil
form
biofilm
mani
control
qs
addit
bcc
abl
surviv
cultur
human
epitheli
cell
macrophag
sever
diseas
may
strain
rather
speciesspecif
howev
may
also
depend
patient
factor
interact
pathogen
note
neither
presenc
cabl
pili
presenc
b
cepacia
epidem
strain
marker
consid
reliabl
indic
virul
transmiss
chronic
infect
may
develop
acut
exacerb
gradual
declin
lung
function
transmiss
speci
replac
burkholderia
spp
caus
chronic
infect
exacerb
associ
acquisit
new
speci
strain
factor
lead
sever
diseas
certain
speci
strain
still
unclear
relev
member
complex
unclear
prompt
accur
laboratori
identif
bcc
import
implic
patient
care
need
prevent
crossinfect
commerci
identif
system
reliabl
use
select
cultur
media
molecular
identif
method
greatli
improv
detect
epidemiolog
b
pseudomallei
total
differ
bcc
wellrecogn
human
pathogen
caus
melioidosi
sever
pneumonia
individu
immunocompet
cf
gene
defect
report
infect
cf
patient
live
travel
endem
area
infect
lead
signific
diseas
bacteria
may
howev
persist
cf
lung
risk
later
reactiv
gramneg
bacilli
eg
achromobact
xylosoxidan
stenotrophomona
maltophilia
pandoraea
apista
gramneg
bacilli
either
preval
cf
maltophilia
recogn
recent
due
improv
laboratori
identif
xylosoxidan
pandoraea
apista
bacteria
may
select
prolong
use
antipseudomon
antibiot
increas
life
expect
cf
patient
recent
studi
maltophilia
support
earlier
observ
organ
may
limit
clinic
signific
cf
despit
increas
cultur
cf
patient
sever
diseas
associ
pulmonari
deterior
intrins
resist
meropenem
acquir
resist
mani
antibiot
cotrimoxazol
treatment
choic
symptomat
infect
best
manag
cotrimoxazoleresist
infect
uncertain
vitro
suscept
test
agent
current
method
reliabl
enough
use
determin
treatment
like
stenotrophomona
achromobact
previous
alcaligen
xylosoxidan
may
chronic
colon
cf
lung
shown
lead
signific
deterior
lung
function
data
need
pandoraea
apista
recent
identifi
cf
sputum
intrins
resist
colistin
may
also
misidentifi
burkholderia
sp
inform
clinic
relev
organ
need
crossinfect
clinic
deterior
describ
six
patient
danish
cf
centr
wide
rang
gramneg
bacteria
isol
cf
sputum
includ
speci
genera
ralstonia
chryseobacterium
comamona
moraxella
acinetobact
bordetella
inquilinu
member
famili
enterobacteriacea
insuffici
data
comment
clinic
relev
bacteria
may
harmless
colon
import
howev
correctli
identifi
associ
signific
diseas
may
recogn
also
may
mistaken
known
pathogen
uk
refer
laboratori
report
suggest
around
bacteria
refer
member
bcc
initi
misidentifi
similar
misidentif
rate
occur
xylosoxidan
atyp
multiresist
form
p
aeruginosa
recent
paper
highlight
difficulti
identifi
cf
bacteria
atyp
phenotyp
use
tradit
method
coloni
morpholog
biochem
identif
author
advoc
use
nucleic
acidbas
identif
method
speciesspecif
pcr
ribosom
rna
gene
sequenc
nontubercul
mycobacteria
ntm
increasingli
recogn
caus
infect
cf
may
partli
clinician
send
sampl
ntm
cultur
laboratori
get
better
isol
ntm
howev
also
thought
genuin
increas
preval
lung
infect
ntm
patient
cf
surviv
longer
autom
liquid
system
allow
rapid
cultur
ntm
may
sensit
tradit
use
lowenstein
jensen
agar
slope
high
number
p
aeruginosa
cf
sputum
howev
caus
problem
decontamin
make
ntm
cultur
difficult
ntm
ubiquit
environ
found
dust
food
drink
water
cf
patient
therefor
repeatedli
expos
ntm
surpris
sputum
infect
infect
cf
restrict
lung
without
dissemin
ntm
diseas
found
patient
aid
studi
usa
cf
centr
cf
patient
year
old
ntm
cultur
least
one
three
sputa
month
met
at
criteria
ntm
diseas
although
relev
criteria
patient
cf
assess
infect
ntm
common
older
patient
associ
better
lung
function
coinfect
aureu
rather
p
aeruginosa
appear
geograph
influenc
overal
preval
rang
new
orlean
boston
uncertain
howev
whether
differ
relat
differ
climat
veget
reflect
antibiot
steroid
usag
cf
clinic
member
mycobacterium
avium
complex
frequent
isol
patient
avium
predomin
speci
almost
patient
uniqu
strain
evid
crossinfect
mix
speci
mycobacterium
abscessu
account
ntm
cultur
us
studi
increasingli
report
cf
patient
europ
seem
associ
sever
infect
research
pathogen
need
abscessu
coloni
either
rough
smooth
depend
express
glycopeptidolipid
gpl
propos
smooth
form
gpl
form
biofilm
vitro
less
pathogenicfavour
colon
wherea
rough
form
produc
littl
gpl
infect
human
monocyt
caus
persist
invas
infect
mous
model
similar
relationship
coloni
morpholog
virul
propos
avium
kansasii
howev
studi
test
clinic
relev
observ
common
bacteria
may
persist
biofilm
abscessu
appear
less
suscept
antibiot
grown
biofilm
plankton
cultur
clinic
relev
ntm
difficult
assess
cf
patient
usual
pathogen
sputum
addit
ntm
differ
speci
may
cultur
differ
occas
difficult
distinguish
repeat
acquisit
loss
environ
establish
infect
isol
therefor
need
identifi
rather
assum
repeat
posit
cultur
mycobacterium
spp
indic
persist
infect
difficulti
identif
chang
taxonomi
mean
previou
infect
attribut
fortuitum
complex
chelona
may
due
abscessu
role
vitro
suscept
test
abscessu
question
correl
clinic
respons
poor
suscept
test
macrolid
clarithromycin
azithromycin
recommend
avium
complex
area
need
work
includ
reliabl
cultur
identif
ntm
clinic
relev
test
measur
antibiot
suscept
understand
pathogen
mechan
particular
abscessu
build
at
guidelin
specif
definit
cf
distinguish
transient
carriag
colon
clinic
infect
need
trial
treatment
variou
speci
aspergillu
commonli
aspergillu
fumigatu
cultur
cf
sputum
fungal
spore
common
air
water
usual
deriv
rot
veget
aspergillu
may
contamin
sputum
contain
even
laboratori
cultur
cf
caus
allerg
bronchopulmonari
aspergillosi
abpa
diagnost
criteria
abpa
cf
publish
patient
treat
steroid
antifung
aspergilloma
also
seen
cf
rare
recent
paper
describ
bronchiti
six
patient
infect
aspergillu
without
featur
abpa
respond
antifung
therapi
scedosporium
apiospermum
also
associ
abpalik
pictur
cf
candida
spp
commonli
cultur
cf
sputum
unexpect
given
much
antibiot
treatment
cf
broad
spectrum
lead
overgrowth
candida
spp
mucos
surfac
cultur
therefor
due
oral
contamin
sputum
colon
sputum
also
possibl
current
evid
signific
role
candida
spp
lower
airway
infect
possibl
role
normal
oral
flora
cystic
fibrosi
sputum
bacteria
usual
label
normal
flora
mouth
upper
airway
often
grown
sputum
even
sampl
taken
bronchoscopi
thought
due
contamin
saliva
howev
bacteria
may
present
larg
number
like
sputum
seed
smallvolum
aspir
multipl
take
place
sputum
two
main
line
investig
focus
bacteria
care
cultur
techniqu
shown
larg
number
divers
anaerob
cultur
cf
sputum
use
rrna
gene
profil
termin
restrict
fragment
length
polymorph
directli
cf
sputum
shown
great
divers
anaerob
aerob
speci
signific
observ
may
flora
bystand
commens
altern
may
actual
pathogen
miss
present
mixtur
assum
pathogen
p
aeruginosa
could
even
explain
cf
patient
may
improv
treat
antibiot
convent
pathogen
resist
vitro
anoth
explan
member
normal
flora
may
interact
convent
pathogen
one
studi
viridantyp
streptococcu
shown
enhanc
pathogen
p
aeruginosa
agar
bead
lung
infect
model
rat
viridanstyp
streptococcu
coagulaseneg
staphylococcu
isol
cf
sputum
also
upregul
p
aeruginosa
gene
includ
code
pathogen
factor
elastas
lasb
respiratori
viral
infect
common
children
rel
wellcontrol
studi
specif
role
respiratori
virus
cf
partli
techniqu
identifi
virus
cultur
serolog
insensit
respiratori
virus
thought
trigger
cofactor
acut
infect
exacerb
copd
propos
may
play
role
develop
chronic
infect
bacteri
pathogen
earli
danish
data
show
cf
patient
like
acquir
first
p
aeruginosa
develop
chronic
pseudomon
infect
octob
marchth
peak
season
respiratori
virus
find
consist
year
spite
major
chang
treatment
bacteri
infect
rapid
technic
advanc
exampl
use
microarray
allow
indepth
studi
role
viral
infect
cf
influenza
signific
impact
patient
cf
antivir
drug
recommend
uk
patient
chronic
lung
diseas
includ
cf
treatment
prevent
exposur
annual
vaccin
also
recommend
patient
cf
microbiolog
cf
complex
pattern
acut
intermitt
eventu
chronic
infect
seen
familiar
pathogen
bacteria
normal
seen
respiratori
tract
encount
relev
new
insight
pathogen
epidemiolog
old
pathogen
cf
assess
signific
microorgan
previous
recogn
cf
investig
although
excit
advanc
basic
scienc
still
need
understand
trigger
exacerb
test
bacteria
cf
laboratori
accur
clinic
relev
result
best
option
prevent
treatment
infect
lesson
learn
complex
interact
bacteria
adapt
chronic
infect
seen
cf
lung
hold
promis
better
manag
infect
cf
may
also
help
develop
strategi
improv
outcom
chronic
infect
lung
elsewher
